Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury
· Financial Post
VANCOUVER, British Columbia & GRAPEVINE, Texas -- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,589,099 on March 31, 2026. The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” includes claims covering methods of treating both confirmed and suspected traumatic brain injury (TBI) using ALPHA-1062. Read More
Visit syntagm.co.za for more information.